Lee Schwartzberg, MD, FACP: Biosimilars and Neutropenia
April 17th 2019Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, discusses his research that showed that the incidence of febrile neutropenia was similar between patients who received reference filgrastim versus those who received a biosimilar.
Suzette Kox, MPharm: Pharmacovigilance and Nonproprietary Names for Biosimilars
April 15th 2019Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the European experience with using nonproprietary names for biosimilar pharmacovigilance.
Lawrence Shulman, MD: The Global Impact of Biosimilar Trastuzumab
January 7th 2019Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the global impact of biosimilar trastuzumab.
Lawrence Shulman, MD: Preparing for Biosimilar Trastuzumab
January 2nd 2019Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the arrival of biosimilar trastuzumab.